FDA Presses Generics Firms to Speed Adoption of QbD, While Questions on Use of Prior Knowledge Persist

FDA officials are telling generic drug makers that the agency will be looking for their abbreviated new drug applications to include the type of pharmaceutical development studies and risk assessments that are spelled out in recent guidelines from the International Conference on Harmonization.